2021
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway
Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, Li X, Fu Y, Wang Z, Li Y, Huang Y, Li F, Wu X, You L, Qin T, Lu Y, Huang X, Ma D, Mills G, Sun C, Chen G. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. Journal Of Experimental Medicine 2021, 219: e20210789. PMID: 34825915, PMCID: PMC8628262, DOI: 10.1084/jem.20210789.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesCell Cycle ProteinsCell Line, TumorEndogenous RetrovirusesEnzyme InhibitorsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHumansImmune Checkpoint InhibitorsMice, Inbred BALB CMice, Inbred C57BLMice, Inbred NODMice, SCIDNeoplasms, ExperimentalProtein-Tyrosine KinasesPyrazolesPyrimidinonesRNA, Double-StrandedSignal TransductionTumor BurdenConceptsImmune checkpoint blockadeAnti-tumor immunityEndogenous retroviral elementsWEE1 inhibitionCheckpoint blockadeCD8+ T cell-dependent mannerSensitivity to immune checkpoint blockadeResponse to immune checkpoint blockadeAnti-tumor T cellsCombination of WEE1 inhibitorT cell-dependent mannerPathway-targeted therapiesMultiple tumor modelsPopulation of patientsEmergence of resistanceDown-regulating FoxM1Viral defense pathwaysPD-L1Tumor regressionCombination therapyTargeted therapyCombination partnerT cellsPatient selectionWEE1 inhibitor
2012
Nanoparticle-based artificial RNA silencing machinery for antiviral therapy
Wang Z, Liu H, Yang S, Wang T, Liu C, Cao Y. Nanoparticle-based artificial RNA silencing machinery for antiviral therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 12387-12392. PMID: 22802676, PMCID: PMC3412013, DOI: 10.1073/pnas.1207766109.Peer-Reviewed Original ResearchConceptsFundamental gene regulatory mechanismsHepatitis C virusGene regulatory mechanismsCultured cellsTarget RNA cleavageSequence-specific mannerCellular interferon responseFunctional genomicsHuman hepatoma cellsRNA interferenceArtificial RNARegulatory mechanismsMouse modelRNA cleavageCultured human hepatoma cellsSpecific mannerHCV RNA levelsRNAXenotransplantation mouse modelHepatoma cellsInterferon responsePotent antiviral activityRNA levelsMachineryProteinase activity
2009
NOD2 regulates hematopoietic cell function during graft-versus-host disease
Penack O, Smith O, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na I, Holland A, Ghosh A, Lu S, Jenq R, Liu C, Murphy G, Brandl K, van den Brink M. NOD2 regulates hematopoietic cell function during graft-versus-host disease. Journal Of Experimental Medicine 2009, 206: 2101-2110. PMID: 19737867, PMCID: PMC2757869, DOI: 10.1084/jem.20090623.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsNOD2 deficiencyHost diseaseCrohn's diseaseExperimental allogeneic bone marrow transplantationAllogeneic bone marrow transplantationHost antigen-presenting cellsAllo-BMT recipientsDevelopment of GVHDExperimental colitis modelHematopoietic cellsHost hematopoietic cellsDonor T cellsIndependent risk factorBone marrow chimerasBone marrow transplantationChimeric recipientsIntestinal inflammationProinflammatory stateColitis modelMarrow transplantationNOD2 mutationsRisk factorsT cellsPaneth cells